BiOkuris

We are delighted to announce an exclusive agreement with Amdis Health Sciences Middle East, marking a significant milestone for BiOkuris as we establish our first footprint beyond the EU. This partnership focuses on our #ChitinGlucan-containing flagship product, BK001, leveraging Amdis Health Sciences' expertise and regional presence. It paves the way to introduce our innovative solutions to new markets and strengthen our global reach. Stay tuned for more updates! #chitinglucan #digestivehealth #Amdis #BiOkuris

We are proud to share the news of our strengthened and expanded partnership with Apriwell! This agreement underscores the robust profile of our #ChitinGlucan-containing flagship product, BK001, which will now be marketed under private label as #Novacalm® in Germany, Austria, and Luxembourg. This milestone reflects our shared commitment to delivering innovative solutions to support better health outcomes. Stay tuned for more updates as we continue to grow together! #chitinglucan #gastrointestinalhealth #BiOkuris #Apriwell

Merci à L’Echo - le Brief de Laurent Fabri de partager notre anniversaire de 10 ans pour KiOmed Pharma ! Fierté, Gratitude et Détermination Fierté du chemin parcouru, gratitude à l’égard des collaborateurs et de tous les stakeholders et determination à poursuivre notre formidable développement ! L'Echo KiOmed Pharma KitoZyme BiOkuris Laurent Fabri Houtaï Choumane

Truly excited to announce the publication of our preclinical study, conducted in collaboration with IFF, where we evaluated the effects of Lactobacillus acidophilus #NCFM and #chitinglucan — both individually and combined —on intestinal pain and inflammation. Impressively, the simultaneous oral administration of these compounds resulted in a twofold superior visceral analgesic effect compared to using each compound alone, showcasing their synergistic properties. Beyond providing significant pain relief, this combination also exhibited strong anti-inflammatory effects, effectively reducing colonic inflammatory lesions and offering sustained relief over time. This synbiotic formulation, BK002, is currently under clinical investigation.   Read the full study, just published in #IJMS: https://lnkd.in/efiC_ujH   #guthealth #BiOkuris #IFF #intestinalpain #IBS

📣 BiOkuris is excited to share that Prof. Edouard Louis (CHU de Liège) will present our poster at UEG - United European Gastroenterology Week in Vienna. The poster will highlight preclinical data revealing the multifaceted benefits of fungal #chitinglucan in gut health, alongside clinical evidence showing its positive impact on #IBS patients.  We look forward to contributing to the ongoing discussions in the field and showcasing these significant findings.   #digestivehealth #UEG #BiOkuris

⭐ BiOkuris is excited to attend CPHI in Milan, where we’ll be meeting with our existing partners and connecting with potential new ones to discuss our growing pipeline of products. If you’ll be there, we’d love to connect. So reach out to us or to our CBO, Benoit Palms — hope to meet you in Milan! 🤝 #CPHI #BiOkuris #chitinglucan #IBS

☀ Good news for IBS patients ... ☀ At the prestigious Faculty Club of KU Leuven, Prof. Jan Tack of UZ Leuven shared very promising interim data on our Vitabiotic’s clinical study. In the 8-week open label phase, we’re seeing a high overall response rate and improvements across all key IBS symptoms, regardless of stool subtype. 🍀 It was refreshing to hear how these ingredients work both individually and synergistically to potentially deliver enhanced results. Dr. Arthur Ouwehand, Technical Fellow at IFF, highlighted the role of Lactobacillus acidophilus NCFM, while Dr. Benoit Palms, Chief Business Officer at BiOkuris, discussed the critical roles of fungal chitin-glucan and VitD3 in BK002’s formula.   ⚡ The energy from this meeting has reignited our excitement as we eagerly await the final results. We remain fully committed to advancing the frontier of gut health innovation! 💡💊   #IBS #Innovation #GutHealth #ChitinGlucan #IFF #BiOkuris #Keyrus

📣  Did you know? Our fungal chitin-glucan is now Monash University Low FODMAP Certified™! 🌿🌿   And this certification also covers 👍: • BK002 – specifically developed for IBS patients  • BK003 – designed for those experiencing IBS-like symptoms   The Monash certification ensures clear identification of low FODMAP products, offering much-needed confidence for those managing digestive issues 👍. In the EU and US alone, over 100 million people suffer from Irritable Bowel Syndrome (IBS) or IBS-like symptoms .   At BiOkuris, we're proud 💪 to contribute to the well-being of those with chronic intestinal conditions by providing innovative, science-backed solutions 🔬 .   #IBS #LowFODMAP #DigestiveHealth #chitinglucan #BiOkuris

📣 Pleased to let you know that our CBO, Benoit Palms, will be at the 46th ESPEN Congress in Milan, proudly presenting our preclinical and clinical findings on the benefits of fungal chitin-glucan in managing chronic intestinal diseases. Looking forward to meet with you in Milan 🇮🇹  ! #chitinglucan #ESPEN2024 #digestivehealth #IBS

🚀 Exciting times ahead as our clinical studies and pipeline progress strongly !  Benoit Palms will be attending #PharmaSynergy, where we are eager to explore new opportunities for co-development and commercialization.  If you're interested in partnering with BiOkuris, let's connect.   🤝 Looking forward to meeting innovative minds and potential partners at #PharmaSynergyOTC in Paris 12 and 13 September !   #BiOkuris #ChitinGlucan #Partnering #guthealth